Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Illumina Announces Sequencing Technology Innovations

Published: Tuesday, April 23, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Rich pipeline delivers the most comprehensive end-to-end solutions for next-generation sequencing.

Illumina has announced a series of product and technology innovations for its powerful sequencing ecosystem - from sample preparation to system enhancements to data analysis - that will enable the next breakthroughs in understanding the genome.

“Illumina has consistently led the market in conceptualizing, developing, and executing on industry-changing sequencing technology, and we continue to provide scientific advances that facilitate fully integrated and highly economical sequencing with very rapid turnaround,” said Jay Flatley, President and Chief Executive Officer of Illumina.

Flatley continued, “These capabilities allow us to continue to meet the evolving needs of our customers, as they develop an ever-increasing range of applications, in new and emerging markets from agrigenomics to molecular diagnostics.”

Sample Prep Evolution
Simplifying and accelerating the sample prep process is fundamental to improving sequencing workflows and decreasing turnaround time, an important factor for sequencing to be adopted in clinical settings. Illumina announced and previewed several innovations in sample preparation technology:

Nextera® Rapid Capture Exome Kits represent a new generation of targeted enrichment products, providing the fastest exome enrichment workflow on both the HiSeq® 2500 and the MiSeq®. With a sample-to-data protocol of less than three days, the kits deliver a 70% speed improvement over current technologies, with a solution optimized for efficient enrichment of coding content. Commercial availability for these kits is scheduled for the end of 1Q’13.
Nextera Rapid Capture Custom Kits enable enrichment of hundreds of kilobases to tens of megabases of custom-selected content. Fully automated probe design through DesignStudio™ and the ability to add content to previously designed panels will be provided. Nextera Rapid Capture Custom Kits will begin shipping in 2Q’13.
TruSeq® DNA PCR-Free Kits are a simple, all-inclusive sample prep solution for whole-genome sequencing providing industry-best genome coverage, the ability to sequence the most challenging regions, and the power to identify variants with high accuracy. These kits will be available to order on January 21, 2013.
Nextera Mate-Pair Sample Preparation Kits offer the only gel-free method for preparing up to 15 kb mate-pair libraries in less than two days with the industry’s lowest DNA input; an ideal approach for de novo sequencing, genome finishing, and the detection of structural variation - even in the most complex genomes such as those derived from cancer. These kits are available for immediate order.
TruSeq Targeted RNA Kits bring a new standard to mid-plex gene expression profiling and validation by overcoming significant challenges in cost and workflow. User-defined custom panels of 12-1,000 assays can be created to target genes, isoforms, splice junctions, and cSNPs, all of which can be added to a wide variety of pre-selected gene panels focused on cell pathways and disease states. Commercial availability for the TruSeq Targeted RNA Kit is scheduled for 1Q’13.

Core Technology Enhancements
Illumina also highlighted a number of core sequencing platform enhancements that will increase the throughput, read lengths, and speed of existing systems, as well as decrease running costs.

A new flow cell technology will provide a significant increase in cluster density and number of reads per flow cell while reducing image-processing time. This new technology improves support for counting applications, lowers the cost per data point, and reduces turnaround time for sequencing projects. First customer experience with these new flow cells will occur in the second half of this year.
A novel library prep method and analysis algorithm, enabled by the acquisition of Moleculo Inc., will produce synthetic read lengths up to 10 kb at an extremely low error rate (Q50 or better). This advancement allows more comprehensive coverage and accurate genotyping of clinically important genes and new applications such as phased resequencing of human genomes, and rapid de novo sequencing of complex plant and animal genomes.
HiSeq 2500 chemistry enhancements empower the industry’s highest daily throughput and drive down the price of whole-genome sequencing. With support of paired 250 base pair read lengths in rapid run mode, the HiSeq 2500 will be capable of generating up to 300 Gb in rapid mode with sample to data in less than three days. These enhancements will be available in the second half of this year.

Informatics Advances
Illumina also shared a development in the evolution of its cloud-based data analysis, storage, and sharing platform, BaseSpace™ (www.illumina.com/basespace):

BaseSpace Apps, a dedicated applications store for BaseSpace, has quickly become a seminal environment for the deployment of informatics tools. Today the community has grown to more than 100 independent developers who are working to bring a wide assortment of analysis tools to a growing cloud-enabled user base.

“Our ability to rapidly innovate across the entire workflow of next-generation sequencing ensures we are better positioned than ever to continue creating and delivering value to both our research and clinical customers,” said Christian Henry, Senior Vice President and General Manager of Illumina’s Genomic Solutions business. “With enhancements to our platform, we continue to set the standard for speed, accuracy, output, and workflow.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Illumina Forms New Company
GRAIL to enable early cancer detection via blood-based screening.
Tuesday, January 12, 2016
Novogene and Illumina Enters into Agreement
Agreement to co-develop NGS diagnostic system for reproductive health and oncology applications.
Wednesday, December 16, 2015
Amoy Diagnostics and Illumina Enter Strategic Collaboration
Collaboration for next-generation sequencing cancer diagnostics in China.
Thursday, October 01, 2015
Illumina Joins WIN Consortium in Personalized Cancer Medicine
A global network of leading academic, industry, insurance and non-profit research organizations.
Thursday, September 24, 2015
MSK and Illumina Launch Comprehensive Circulating Tumor DNA Program
Collaboration aims to determine range of opportunities for non-invasive cancer diagnosis and monitoring.
Thursday, September 17, 2015
Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
Collaboration highlights the ever-increasing importance of genomics to improve healthcare in China.
Tuesday, August 25, 2015
Discordant NIPT Test Results May Reflect Presence of Maternal Cancer
Results published in Journal of the American Medical Association.
Tuesday, July 14, 2015
Illumina Announces Oncology CDx Partnership with AstraZeneca, Janssen and Sanofi
Illumina, forms collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing (NGS)-based oncology test system.
Thursday, August 21, 2014
Illumina Appoints Senior VP of Oncology
Company names Tina S. Nova as Senior Vice President and General Manager of oncology.
Tuesday, July 15, 2014
Amgen and Illumina Enter Agreement
Illumina to develop IVD kit on its FDA-cleared MiSeqDx™ NGS instrument for Amgen’s Vectibix (Panitumumab).
Monday, January 20, 2014
Illumina Technology Enables Findings of COGS
Custom iSelect® genotyping array designed in collaboration with consortia to advance understanding of cancer.
Tuesday, May 28, 2013
Caris Life Sciences Selects Illumina’s MiSeq® System
Collaboration enhances breadth and depth of therapeutic information to help oncologists better personalize cancer treatment.
Friday, November 09, 2012
Illumina Announces Scale-Up of Genome Analyzers at the Broad Institute
Broad Institute has purchased 30 additional Genome Analyzers, increasing its total installed base of Illumina systems to 89.
Friday, November 06, 2009
Illumina Advances Genetic Analysis of Cancer
Illumina is launching software tools that enable customers to use Infinium™ SNP genotyping data.
Friday, December 16, 2005
Scientific News
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!